Holen Sie sich die Stockscreener-App
34.71
7.64%
-2.87
Schlusskurs vom Vortag:
$37.58
Offen:
$37.01
24-Stunden-Volumen:
8.76M
Relative Volume:
1.50
Marktkapitalisierung:
$25.07B
Einnahmen:
$8.26M
Nettoeinkommen (Verlust:
$-397.91M
KGV:
-68.92
EPS:
-0.5036
Netto-Cashflow:
$-758.56M
1W Leistung:
-4.38%
1M Leistung:
+2.57%
6M Leistung:
+19.94%
1J Leistung:
+190.70%
1-Tages-Spanne:
$34.69
$37.13
1-Wochen-Bereich:
$34.69
$37.81
52-Wochen-Spanne:
$11.85
$37.97
Roivant Sciences Ltd Stock (ROIV) Company Profile
Firmenname
Roivant Sciences Ltd
Sektor
Branche
Telefon
441-295-5950
Adresse
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
34.71 | 26.61B | 8.26M | -397.91M | -758.56M | -0.5036 |
VRTX
Vertex Pharmaceuticals Inc
|
541.69 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
794.19 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,023.21 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.99 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
207.88 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-20 | Eingeleitet | Bernstein | Outperform |
| 2025-09-02 | Eingeleitet | Citigroup | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-01-05 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-17 | Eingeleitet | Guggenheim | Buy |
| 2023-06-08 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-27 | Eingeleitet | JP Morgan | Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-15 | Eingeleitet | Goldman | Buy |
| 2021-11-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-28 | Eingeleitet | Citigroup | Buy |
| 2021-10-26 | Eingeleitet | Cowen | Outperform |
| 2021-10-26 | Eingeleitet | Jefferies | Buy |
| 2021-10-26 | Eingeleitet | Truist | Buy |
Alle ansehen
Roivant Sciences Ltd Aktie (ROIV) Neueste Nachrichten
Roivant (NASDAQ: ROIV) CIO sells option shares near $37 - Stock Titan
ROIV Stock Nears Record High –Retail Traders See Breakout After Surprise Earnings Beat - Stocktwits
107,786 Shares in Roivant Sciences Ltd. $ROIV Purchased by Great Lakes Advisors LLC - MarketBeat
Is Roivant Sciences (ROIV) Fully Valued As First Quarter Results Show A Narrower Loss? - Sahm
Roivant Sciences (ROIV) holder plans new sale after $17M June trade - Stock Titan
Roivant Sciences Insider Sold Shares Worth $24,160,402, According to a Recent SEC Filing - marketscreener.com
Roivant President, CIO Mayukh Sukhatme disposes of USD 24.12 million in common shares - Bitget
Roivant Sciences (NASDAQ:ROIV) Insider Mayukh Sukhatme Sells 243,177 Shares - MarketBeat
Mayukh Sukhatme Sells 284,707 Shares of Roivant Sciences (NASDAQ:ROIV) Stock - MarketBeat
Roivant (ROIV) CIO sells shares after exercising $3.85 options - Stock Titan
Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Roivant Sciences stock hits all-time high at 37.06 USD By Investing.com - Investing.com Australia
Roivant (NASDAQ: ROIV) holder eyes new sale after tens of millions sold - Stock Titan
Roivant Sciences (ROIV) Holds Steady at $36.2 as Shares Consolidate Between Support and ResistanceDefined Outcome ETF - vinanet.vn
Roivant Sciences (NASDAQ:ROIV) Sets New 1-Year HighHere's Why - MarketBeat
Roivant Sciences stock hits all-time high at 37.06 USD - Investing.com
Why Is Roivant (NASDAQ:ROIV) in NASDAQ Composite Focus Before Results? - Kalkine Media
Why Is Roivant (NASDAQ:ROIV) a Nasdaq Healthcare Stock to Watch? - Kalkine Media
Roivant Sciences Ltd. (ROIV) Stock Analysis: Exploring a 15.52% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews
Roivant Sciences Ltd (ROIV) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
How Investors May Respond To Roivant Sciences (ROIV) Narrowing Losses Despite Weaker Quarterly Revenue - simplywall.st
Royal Bank of Canada Decreases Position in Roivant Sciences Ltd. $ROIV - MarketBeat
Empowered Funds LLC Buys 267,686 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Handelsbanken Fonder AB Has $6.27 Million Position in Roivant Sciences Ltd. $ROIV - MarketBeat
9 Health Care Stocks Whale Activity In Today’s Session - Benzinga
Roivant Sciences Ltd. (ROIV) Stock Forecasts - Yahoo Finance
How Roivant Sciences Ltd. (ROIV) Affects Rotational Strategy Timing - Stock Traders Daily
Roivant Sciences Ltd. (ROIV) Stock Price, News, Quote & History - Yahoo! Finance Canada
Roivant Sciences Ltd (ROIV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Citi Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $46 - Moomoo
Roivant Sciences (ROIV) Is Up 7.2% After Narrower Net Loss Despite Lower Quarterly Revenue - webull.com
J.P. Morgan Maintains Roivant Sciences(ROIV.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Roivant Sciences Ltd. (ROIV) Stock Analysis: Strong Buy Ratings And 15% Upside Potential - DirectorsTalk Interviews
Is Roivant Sciences’ (ROIV) Cost Discipline Offsetting Slower Revenue Enough to Refresh Its Story? - Yahoo Finance
Is Roivant Sciences (ROIV) Overvalued On First Quarter Results? - Yahoo Finance
Bank of America Corp DE Has $87.64 Million Stock Position in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences: The Balance Sheet Has Become A Strategic Weapon - Seeking Alpha
Sei Investments Co. Acquires 33,508 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences (ROIV) Stock Rally Leans On Cash As Losses Persist - simplywall.st
Piper Sandler Maintains Roivant Sciences(ROIV.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Guggenheim Issues Positive Forecast for Roivant Sciences (NASDAQ:ROIV) Stock Price - MarketBeat
Roivant Sciences Ltd (ROIV) Stock News Today - TradingKey
Guggenheim Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $42 - Moomoo
Roivant Sciences Ltd. Q1 2026 Earnings Call Summary - finance.yahoo.com
Roivant Sciences Q1 Earnings Call Highlights - MarketBeat
Assenagon Asset Management S.A. Acquires 1,286,464 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
TD Cowen raises Roivant Sciences stock price target to $50 on execution - Investing.com South Africa
Roivant Sciences Ltd. Stock 12‑Month Price Target Raised to $39.73, Implies 15% Upside - TradingView
Earnings call transcript: Roivant posts Q1 2026 EPS beat, revenue miss as shares slip - Investing.com Nigeria
Roivant Sciences earnings beat by $0.04, revenue fell short of estimates - Investing.com
Finanzdaten der Roivant Sciences Ltd-Aktie (ROIV)
Umsatz
Nettogewinn
Free Cashflow
ENV
Roivant Sciences Ltd-Aktie (ROIV) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sukhatme Mayukh | President & CIO |
Aug 19 '26 |
Option Exercise |
3.85 |
172,899 |
665,661 |
18,803,638 |
| Sukhatme Mayukh | President & CIO |
Aug 21 '26 |
Option Exercise |
3.85 |
144,756 |
557,311 |
18,775,495 |
| Sukhatme Mayukh | President & CIO |
Aug 20 '26 |
Option Exercise |
3.85 |
17,519 |
67,448 |
18,648,258 |
| Sukhatme Mayukh | President & CIO |
Aug 19 '26 |
Sale |
37.17 |
172,899 |
6,426,656 |
18,630,739 |
| Sukhatme Mayukh | President & CIO |
Aug 21 '26 |
Sale |
36.48 |
144,756 |
5,280,699 |
18,630,739 |
| Sukhatme Mayukh | President & CIO |
Aug 20 '26 |
Sale |
37.30 |
17,519 |
653,459 |
18,630,739 |
8.37%
0.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):